Clinical trial · Interventional
PET and MRI in Prognosis Prediction of NPC
Prognostic Value of the Integrated PET/MRI in Patients With Nasopharyngeal Carcinoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Nasopharyngeal carcinoma (NPC) differs from other head and neck malignancies terms of its epidemiology, pathology, and treatment outcome. Integrated PET/MRI is a new imaging modality, which can simultaneously acquire PET and MRI images. Considering the lack of reports on the use of hybrid PET/MRI systems in prognosis prediction in NPC, the investigators conduct this prospective study to investigate the roles of integrated PET/MRI parameters for predicting treatment outcome and prognosis in patients with NPC.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Nasopharyngeal Carcinoma | Nasopharyngeal Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| integrated PET/MRI | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- integrated PET/MRI
- description
- The participants receive an integrated 18F-FDG PET/MRI during tumor staging.
- interventionNames
- Device: integrated PET/MRI
Primary outcomes (1)
- measure
- Overall survival
- timeFrame
- 3 years
- description
- Being calculated from the date of diagnosis to the date of death or censor at the date of the last follow- up for surviving patients.
Secondary outcomes (1)
- measure
- Recurrence-free survival
- timeFrame
- 3 years
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
Show eligibility criteria text
Inclusion Criteria: 1. Biopsy proven primary nasopharyngeal carcinoma 2. Age \> or = 20 3. Willing to receive therapy 4. The ability to provide written informed consent and receive the scheduled scans Exclusion Criteria: 1. Woman with pregnancy or during lactation 2. A history of other malignancies or concomitant cancers in different anatomical locations 3. Not suitable to receive the PET scan such as serum glucose levels of \> 200 mg/dL or space phobia
References
Publications (1)
- DERIVEDChan SC, Ng SH, Yeh CH, Lin YC, Lin CY, Wang JH, Cheng NM, Chen SH, Chang KP, Hsieh JC. Prognostic utility of 18F-FDG PET/MRI with intravoxel incoherent motion imaging in nasopharyngeal carcinoma. Eur J Nucl Med Mol Imaging. 2025 Dec;53(1):338-349. doi: 10.1007/s00259-025-07425-6. Epub 2025 Jul 2. PMID 40601020